Viral vectors are pivotal in the delivery of advanced therapies, facilitating gene transfer for the treatment of inherited disorders, cancer, and other severe diseases. However, the manufacturing of these vectors remains a significant bottleneck, primarily due to high costs, scalability challenges, and process variability. As the viral vector landscape evolves, there is a pronounced shift toward enhancing commercial production capabilities, moving beyond early clinical supply. This transition necessitates a coordinated approach to optimizing both upstream and downstream processes, underpinned by robust analytics and scalable design methodologies.
Key to this optimization is the choice of producer cell lines and culture formats, with HEK293 systems gaining favor due to their scalability and product quality. The complexities of large-scale cGMP production of HEK293 cell banks underscore the need for meticulous banking conditions to ensure reliable post-thaw recovery. Furthermore, process development must prioritize critical quality attributes, balancing yield with product integrity. As the industry advances toward commercial-scale production, integrating automation and high-throughput tools will be essential for improving efficiency, reducing costs, and ultimately expanding patient access to next-generation therapies.
Use the database as your supply chain compass →
